Tadeusz Robak, MD of the Poznań University of Medical Sciences in Poland provides a summary of a phase II clinical trial assessing rozanolixizumab to treat people with primary immune thrombocytopenia.
Rozanolixizumab is an anti-Fc receptor antibody and results of the study showed that the drug was safe with none of the serious adverse events presented in the trial to be drug-related. Furthermore, dose-dependent increases in platelet levels and dose-dependent decreases in IgG were observed. A phase III study is in development.
Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts (<100,000/mL). Symptoms and severity vary greatly in this population but can include petechiae, purpura, bruising, and excessive bleeding.
To learn more about other rare bleeding disorders, visit checkrare.com/diseases/blood-diseases/